Chicago, IL - June 9, 2009- Kevin Matras shows how to calculate a stock's price target and how to find stocks currently trading below them. Stocks in this week's article include Air Methods Corp. (AIRM), Consol Energy, Inc. (CNX), Consolidated Water Co., Ltd. (CWCO), Newmont Mining Corp. (NEM) and Noven Pharmaceuticals, Inc. (NOVN).

Screen of the Week written by Kevin Matras of Zacks Investment Research:

I wrote about this back in February when the market was putting in its lows and everyone was wondering what their stock's price target was or how low it was going to go.

Today, after a pretty big run up, people are still wondering what their stock's price target is, but now they're wondering how high it's going to go.

Either way, it's important for everyone to know how to calculate their stock's price target.

You can

...

The Mighty Wal-Mart Stores, Inc. (NYSE:WMT) is less than $2 away from its 52-week low of $46.25 and shares closed the day after-hours at $48.04, could this be the time to buy? Wal-Mart reports the following in the coming weeks: May 14, 2009 Q1 2010 Earnings Release - 12:00PM EDT Add to calendar May 14, 2009 Q1 2010 Pre-recorded Earnings Conference Call - 7:30AM EDT...

Baxter International, Inc. (BAX) is a global medical products and services company with expertise in medical devices, pharmaceuticals, and biotechnology. The company is comprised of three operating segments: BioScience, Medication Delivery and Renal.

We believe these markets will remain relatively insulated from the current economic turmoil and provide investors with good quality returns on a risk-adjusted basis. Baxter's strong market position is demonstrated in its recent quarterly and annual performance that exceeded their prior estimates.

We remain bullish on this stock and believe it provides a less risky vehicle during the current economic turbulence. We believe BAX should trade at a 15% premium to the group P/E/G average of 1.2. The resulting P/E is 18.6x 2009, producing a target price of $64.65 per share. "BAX" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Baxter International, Inc. (

Baxter International, Inc. (BAX) is a global medical products and services company with expertise in medical devices, pharmaceuticals and biotechnology. BAX operates three main lines of business: BioScience, Medication Delivery, and Renal.

We believe these markets will remain relatively insulated from the current economic turmoil, providing investors good quality returns on a risk-adjusted basis. Baxter's strong market position is demonstrated in its recent quarterly performance that exceeded estimates and led management to increase fiscal 2008 EPS guidance for the second quarter in a row.

Our 2008 EPS estimate remains within management's guidance of $3.35-$3.37. We believe BAX should trade at a 20% premium to the group P/E/G average of 1.2. The resulting P/E is 19.7x 2008, producing a target price of $66.25.

Read the full analyst report on BAX.

"BAX" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

Baxter International (BAX) is a global medical products and services company with expertise in medical devices, pharmaceuticals and biotechnology. The company operates through three main lines of business: BioScience, Medication Delivery and Renal.

We believe these markets will remain relatively insulated from the current economic turmoil, providing investors good quality returns on a risk-adjusted basis. Baxter's strong market position is demonstrated in its recent quarterly performance that exceeded estimates and led the management to increase fiscal 2008 EPS guidance for the second quarter in a row.

The company's third quarter results exceeded management s guidance and beat our estimates on higher revenues and expanding margins. As a result, management increased its guidance, giving a boost to our estimates. Our estimate increases $0.07 to $3.36, reflecting tighter margin guidance and lower share count. Such a strong increase in guidance in the face of currency headwinds points to greater certainty that stronger fundamentals

...

October 7, 2008 – Solar stocks haven’t been getting any breaks lately. On Friday, the industry got much needed long-term visibility and Federal support through the extension of renewable tax credits, which will be a huge boost to sales in the U.S. markets, but the solar stocks suffered amidst a broader selloff as the Street focused on the dismal outlook for the domestic and global economies. And then this morning, Goldman Sachs’ solar analyst Michael Molnar cut First Solar (Nasdaq:FSLR) and SunPower (SPWRA) to Sell ratings citing oversupply in the sector for modules and not enough subsidies in Europe, sending the group reeling in pre-market activity. Here is our take: 1.     Molnar’s comments seem to us to coming late. That the solar landscape, both in terms of feedstock production and module production is becoming increasing crowded and competitive, which will lead to commoditization, oversupply and downward pressure is no new ...

Advanced Medical Optics, Inc. (EYE) reported Q2 EPS that were lower than our estimate by $0.05 on revenue that exceeded our forecast. We lowered our FY08/FY09 EPS estimates. Due to the slowdown in the U.S. economy that is having a greater-than-expected negative impact on the elective refractive procedure market, the management lowered its FY08 EPS guidance.

This guidance includes plans to cut fixed costs primarily in manufacturing and SG&A operations to provide some support to earnings growth and maximize cash flow in a weak economy. Our price target is based on roughly 15x FY09 EPS estimate. At its current price of $20.32 per share, AMO is trading at roughly 14x our 2009 earnings estimate of $1.46 per share and roughly a 0.7x P/E/G on 2009 EPS estimate, at a discount to the peer group P/E multiple of roughly 16x and at a discount to the group P/E/G of

...